29 research outputs found
B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma
B cells are known to contribute to the anti-tumor immune response, especially in immunogenic tumors such as melanoma, yet humoral immunity has not been characterized in these cancers to detail. Here we show comprehensive phenotyping in samples of circulating and tumor-resident B cells as well as serum antibodies in melanoma patients. Memory B cells are enriched in tumors compared to blood in paired samples and feature distinct antibody repertoires, linked to specific isotypes. Tumor-associated B cells undergo clonal expansion, class switch recombination, somatic hypermutation and receptor revision. Compared with blood, tumor-associated B cells produce antibodies with proportionally higher levels of unproductive sequences and distinct complementarity determining region 3 properties. The observed features are signs of affinity maturation and polyreactivity and suggest an active and aberrant autoimmune-like reaction in the tumor microenvironment. Consistent with this, tumor-derived antibodies are polyreactive and characterized by autoantigen recognition. Serum antibodies show reactivity to antigens attributed to autoimmune diseases and cancer, and their levels are higher in patients with active disease compared to post-resection state. Our findings thus reveal B cell lineage dysregulation with distinct antibody repertoire and specificity, alongside clonally-expanded tumor-infiltrating B cells with autoimmune-like features, shaping the humoral immune response in melanoma
Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum 3rd trial)
The psoriasis-protective IL23R A/Glu381 allele promotes interleukin-23 unresponsiveness in human memory T helper (Th) 17 cells and impairs Th17 response in patients with psoriasis
Unmasking the pathological and therapeutic potential of histone deacetylases for liver cancer
Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum 3rd trial).
Background: Locally advanced rectal cancer (LARC) is a heterogeneous group of tumors where a risk-adapted
therapeutic strategy is needed. Short-course radiotherapy (SCRT) is a more convenient option for LARC patients than preoperative long-course RT plus capecitabine. Histone-deacetylase inhibitors (HDACi) have shown activity in
combination with RT and chemotherapy in the treatment of solid tumors. Valproic acid (VPA) is an anti-epileptic drug with HDACi and anticancer activity. In preclinical studies, our group showed that the addition of HDACi,
including VPA, to capecitabine produces synergistic antitumour effects by up-regulating thymidine phosphorylase
(TP), the key enzyme converting capecitabine to 5-FU, and by downregulating thymidylate synthase (TS), the 5-FU target.
Methods/Design: Two parallel phase-1 studies will assess the safety of preoperative SCRT (5 fractions each of 5 Gy, on days 1 to 5) combined with (a) capecitabine alone (increasing dose levels: 500â825 mg/m2/bid), on days 1â21, or (b) capecitabine as above plus VPA (oral daily day â14 to 21, with an intra-patient titration for a target serum level of 50â100 microg/ml) followed by surgery 8 weeks after the end of SCRT, in low-moderate risk RC patients. Also, a randomized phase-2 study will be performed to explore whether the addition of VPA and/or capecitabine to
preoperative SCRT might increase pathologic complete tumor regression (TRG1) rate. A sample size of 86 patients
(21-22/arm) was calculated under the hypothesis that the addition of capecitabine or VPA to SCRT can improve the
TRG1 rate from 5% to 20%, with one-sided alpha = 0.10 and 80% power. Several biomarkers will be evaluated comparing normal mucosa with tumor (TP, TS, VEGF, RAD51, XRCC1, Histones/proteins acetylation, HDAC isoforms) and on blood samples (polymorphisms of DPD, TS, XRCC1, GSTP1, RAD51 and
XRCC3, circulating endothelial and progenitors cells; PBMCs-istones/proteins acetylation). Tumor metabolism will be measured by 18FDG-PET at baseline and 15 days after the beginning of SCRT.
Discussion: This project aims to improve the efficacy of preoperative treatment of LARC and to decrease the
inconvenience and the cost of standard long-course RT. Correlative studies could identify both prognostic and predictive biomarkers and could add new insight in the mechanism of interaction between VPA, capecitabine and RT.
EudraCT Number: 2012-002831-28.
Trial registration: ClinicalTrials.gov number, NCT0189810
Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer
B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma
Abstract B cells are known to contribute to the anti-tumor immune response, especially in immunogenic tumors such as melanoma, yet humoral immunity has not been characterized in these cancers to detail. Here we show comprehensive phenotyping in samples of circulating and tumor-resident B cells as well as serum antibodies in melanoma patients. Memory B cells are enriched in tumors compared to blood in paired samples and feature distinct antibody repertoires, linked to specific isotypes. Tumor-associated B cells undergo clonal expansion, class switch recombination, somatic hypermutation and receptor revision. Compared with blood, tumor-associated B cells produce antibodies with proportionally higher levels of unproductive sequences and distinct complementarity determining region 3 properties. The observed features are signs of affinity maturation and polyreactivity and suggest an active and aberrant autoimmune-like reaction in the tumor microenvironment. Consistent with this, tumor-derived antibodies are polyreactive and characterized by autoantigen recognition. Serum antibodies show reactivity to antigens attributed to autoimmune diseases and cancer, and their levels are higher in patients with active disease compared to post-resection state. Our findings thus reveal B cell lineage dysregulation with distinct antibody repertoire and specificity, alongside clonally-expanded tumor-infiltrating B cells with autoimmune-like features, shaping the humoral immune response in melanoma
A Combination of Preliminary Electroweak Measurements and Constraints on the Standard Model, 2001. Prepared for the 2000 summer conferences
This note presents a combination of published and preliminary electroweak results from the four LEP collaborations and the SLD collaboration which were prepared for the 2000 summer conferences. Averages from Z0 resonance results are derived for hadronic and leptonic cross sections, the leptonic forward-backward asymmetries, the polarisation asymmetries, the bbbar and ccbar partial widths and forward-backward asymmetries and the qqbar charge asymmetry. Above the Z0 resonance, averages are derived for di-fermion cross sections and asymmetries, W-pair, Z-pair and single-W production cross section, electroweak gauge boson couplings and W mass and decay branching ratios. The major changes with respect to results presented in summer 1999 are final Z0 lineshape results from LEP, updates to the W mass and gauge-boson couplings from LEP, and ALR from SLD. The results are compared with precise electrowea